Release Date: July 31, 2025
Expiration Date: July 31, 2027
Activity Overview
The BURST CME™ format is an inline, on-demand video program designed to deliver concise modular education. In this first module, Dr Aaron D. Berger reviews the limitations of prostate-specific antigen (PSA) testing for the detection of prostate cancer, the plethora of ancillary biomarker tests that are currently available, and how he incorporates biomarker testing into daily practice.
Target Audience
This educational activity is primarily directed toward urologists. Other clinicians who diagnose prostate cancer are welcome to participate as well.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply biomarker testing to guide diagnostic evaluation in patients with a high risk of prostate cancer.
- Integrate biomarker testing and magnetic resonance imaging to improve risk stratification and early detection in patients with a high risk of prostate cancer.
- Implement long-term monitoring strategies for patients with a low risk of prostate cancer.
Aaron D. Berger, MD
Chief Medical Officer, Director Clinical Research
Associated Urological Specialists, Solaris Health Partners
Chicago Ridge, IL
Disclosures: Speaker: Accord Biopharma, Astellas, Bayer, BioProtect, Ferring Pharmaceuticals, Pfizer, Sumitomo, Veracyte
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here